Standout Papers

Secukinumab in Plaque Psoriasis — Results of Two Phase... 2005 2026 2012 2019 1.4k
  1. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials (2014)
    Richard G. Langley, Boni E. Elewski et al. New England Journal of Medicine
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (2008)
    Craig L. Leonardi, Alexa B. Kimball et al. The Lancet
  3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008)
    Kim Papp, Richard G. Langley et al. The Lancet
  4. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial (2005)
    Stephen K. Tyring, Alice B. Gottlieb et al. The Lancet
  5. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial (2005)
    Kristian Reich, Frank O. Nestlé et al. The Lancet
  6. Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis (2012)
    Kim Papp, Craig L. Leonardi et al. New England Journal of Medicine
  7. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial (2007)
    Alan Menter, Stephen K. Tyring et al. Journal of the American Academy of Dermatology
  8. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials (2015)
    C.E.M. Griffiths, Kristian Reich et al. The Lancet
  9. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis (2016)
    Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine
  10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial (2017)
    Andrew Blauvelt, Kim Papp et al. Journal of the American Academy of Dermatology
  11. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) (2007)
    J.‐H. Saurat, G Stingl et al. British Journal of Dermatology
  12. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction (2005)
    Kim Papp, Stephen K. Tyring et al. British Journal of Dermatology
  13. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) (2015)
    Kim Papp, Kristian Reich et al. Journal of the American Academy of Dermatology
  14. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study (2009)
    Arthur Kavanaugh, Iain B. McInnes et al. Arthritis & Rheumatism
  15. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials (2018)
    Kenneth B. Gordon, Bruce Strober et al. The Lancet
  16. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (2017)
    Kristian Reich, Kim Papp et al. The Lancet
  17. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis (2017)
    Kim Papp, Andrew Blauvelt et al. New England Journal of Medicine
  18. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) (2005)
    Michelle A. Lowes, Francesca Chamian et al. Proceedings of the National Academy of Sciences
  19. A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis (2016)
    Kim Papp, Kristian Reich et al. British Journal of Dermatology
  20. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials (2021)
    Emma Guttman‐Yassky, Henrique D. Teixeira et al. The Lancet
  21. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial (2016)
    Robert Bissonnette, Kim Papp et al. British Journal of Dermatology
  22. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial (2019)
    Emma Guttman‐Yassky, Diamant Thaçi et al. Journal of Allergy and Clinical Immunology
  23. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial (2022)
    April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology
  24. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies (2021)
    Kim Papp, Jacek C. Szepietowski et al. Journal of the American Academy of Dermatology
  25. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial (2022)
    Bruce Strober, Diamant Thaçi et al. Journal of the American Academy of Dermatology
  26. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial (2021)
    Kristian Reich, Kim Papp et al. The Lancet
  27. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis (2022)
    Eric L. Simpson, Kim Papp et al. JAMA Dermatology

Immediate Impact

3 by Nobel laureates 9 from Science/Nature 119 standout
Sub-graph 1 of 11

Citing Papers

Atopic dermatitis
2025 Standout
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
53 intermediate papers

Works of Kim Papp being referenced

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials
2024
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
2020
and 43 more

Author Peers

Author Last Decade Papers Cites
Kim Papp 23568 15724 6964 528 31.4k
Kristian Reich 19466 13460 4889 491 25.3k
Mark Lebwohl 22034 17465 5458 807 34.6k
Alice B. Gottlieb 22317 11858 8621 573 30.3k
Alan Menter 18409 11772 4555 375 24.5k
Joel M. Gelfand 13768 8901 4978 277 20.9k
Juliet N. Barker 16763 8700 2705 539 30.3k
Richard G. Langley 14165 9354 3341 255 18.4k
Giampiero Girolomoni 12086 9588 3699 539 23.0k
L. Puig 10766 7372 3649 617 17.5k
C. Paul 8430 8425 2895 409 15.9k

All Works

Loading papers...

Rankless by CCL
2026